Elastagen Completes A$13m Series B Equity Financing
Sydney clinical-stage medical company Elastagen closed a A$13 million Series B, adding KIP, AMOREPACIFIC Ventures and Wellcome Trust to its existing backers; KIP's Sangwoo Lee joined the board.
Company
Every investor coverage indicates participated in a round ATP Innovations raised.
Companies ATP Innovations acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming ATP Innovations. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sydney clinical-stage medical company Elastagen closed a A$13 million Series B, adding KIP, AMOREPACIFIC Ventures and Wellcome Trust to its existing backers; KIP's Sangwoo Lee joined the board.
Sydney medical device company Elastagen completed a first-in-human study of its synthetic elastin skin products and plans two further trials, targeting a European launch in early 2013.